Earnings ·
ProMIS Neurosciences Inc. reported second quarter 2026 financial results and announced positive interim safety and…
PMNProMIS Neurosciences Inc.
ProMIS Neurosciences Inc. reported second quarter 2026 financial results and announced positive interim safety and biomarker data from its Phase 1b PRECISE-AD trial of PMN310 in early Alzheimer's disease. The company recorded a net loss of $11.7 million, or $1.28 per share, compared to a loss of $10.1 million, or $7.26 per share, in the prior year period. Cash and short-term investments totaled $53.4 million as of June 30, 2026, providing operational runway through 2027. The interim analysis showed zero cases of amyloid-related imaging abnormalities-edema (ARIA-E) across all participants and no treatment-related serious adverse events. Biomarker analyses indicated early declines in plasma pTau217 and CSF MTBR-tau243. ProMIS Neurosciences is a clinical-stage biotechnology company focused on developing antibody therapeutics for neurodegenerative diseases.